Our mechanistic studies with berberine and metformin provide evidence in favor of a dose-dependent tumor suppressive role of AMPK in PDAC cells and offer the bases for novel therapeutic strategies for the treatment of pancreatic cancer, a devastating disease with limited survival option. Here, PRKAA1 is linked to familial pancreatic carcinoma.